There are over 40 medicines currently approved or used off label to treat obesity, in addition there are more than 20 innovative products in clinical development
Dallas, Texas (PRWEB) October 02, 2013
Advances in the Obesity Market helps examine why the obesity market is of such importance across established and emerging economies and how current interventions measure up. In July 2011, the American Association of Clinical Endocrinologists (AACE) reclassified obesity as a diseased state, not a condition, in order to move it up the US healthcare agenda. In 2012, the FDA reviewed its stance on anti-obesity products and approved two new products that were previously declined.
As it stands, there are over 40 medicines currently approved or used off label to treat obesity, in addition there are more than 20 innovative products in clinical development. This new report on advances in the obesity market (http://www.marketreportsonline.com/279318.html ) examines the latest products and devices in development and compares them to those currently available, gathering opinions from key industry leaders to highlight the fast-moving changes that are affecting this profit potential market.
This report provides you with a detailed analysis and key opinions on the current and future obesity market including: Detailed review of the current obesity market, answering ‘Where are we now?’ for both established and emerging economies, Comprehensive insight into newly approved pharmaceuticals and medical devices, analyzing how they compare to established brands, Assessment of key products and devices in development, identifying ‘Ones to Watch’ in late-stage clinical development, Reviews of products and devices that are ‘Waiting in the Wings’ in early-stage clinical development where PoC data is being gathered and Analyses of potential ‘Long Shots’ representing new and innovative products where the rationale has yet to be fully tested.
This report provides a comprehensive overview of existing anti-obesity therapies and surgical interventions. It provides a systematic appraisal of each market segment highlighting both the leading players and new entrants. The report includes thoughts from key opinion leaders across the globe to find out where the key challenges and opportunities exist for both pharma and medical device manufacturers.
Answering critical questions, this report’s comprehensive Table of Contents can be explored at http://www.marketreportsonline.com/279318-toc.html :
- Why is obesity important to the pharmaceutical industry, why now?
- What issues have been faced in the past and how can this be avoided for the future?
- How does Xenical stack up against Belviq?
- Have GLP-1 analogues got what it takes to treat obesity?
Will Arrowhead Research’s adipotide promote weight loss and reduce the symptoms of diabetes in the clinic?
- Is gastric banding still popular among surgeons and obese patients?
- What opportunities exist for the introduction of intragastric balloons in the US?
- Will J&J remain the leading medical devices company for the foreseeable future?
- Can BAROnova’s TransPyloric Shuttle fill the gap between pharmacotherapy and interventional surgery?
Another report Disease and Therapy Review: Obesity, available at http://www.marketreportsonline.com/41871.html , provides an overview of obesity and related conditions, with prevalence and mortality numbers, percentages and trends for major countries worldwide and an overview of treatment. Dosing and treatment cost information is provided for various treatment types. General information on the obesity market, as well as sales of leading drugs and therapies are provided. Here is the brief table of contents covered in this report:
Table of Contents
General description of the condition
Increased risk of comorbidities
Causes of obesity
II. Prevalence and Mortality
Prevalence Table-Obesity & Overweight (Canada, US, Argentina, Brazil, Chile, Colombia, Peru, England, France, Germany, Greece, Italy, Spain, UK, China, India, Japan, South America, Northwest Europe, South Europe, East Europe, Worldwide)
Prevalence Table-Obesity Only (Canada, US, Mexico, Argentina, Brazil, Chile, Colombia, Poland, Romania, Russia, England, Sweden, UK, Greece, Italy, Spain, France, Germany, China, Japan, Korea, Bangladesh, India, Iran, Pakistan, Indonesia, Malaysia, Philippines, Thailand, Vietnam, Saudi Arabia, Turkey, Egypt, Kenya, Morocco, Nigeria, South Africa, Australia, By Region, Worldwide)
Prevalence Table-Morbid Obesity (Canada, US, France, Chile)
Mortality Table-Obesity Only (US, US and Canada, Western Europe, Worldwide)
III. Treatment and Dosing
IV. Treatment Costs
Costs for commonly prescribed non-generic drugs
Direct healthcare costs of obesity and comorbidities
V. Market Size
Sales information for key pharmaceuticals and procedures
Order a copy of the report at http://www.marketreportsonline.com/contacts/purchase.php?name=41871 .
Explore more reports on the healthcare market at http://www.marketreportsonline.com/cat/healthcare-market-research.html .
MarketReportsOnline.com is an online database of regional industry research reports, company profiles and SWOT analysis studies for multiple industries and organizations.